載入...
Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most common cancer-causing HPV types (HPV 31/33/45/52/58) after HPV 16/18. Phase III clinical studies have demonstrated h...
Na minha lista:
| 發表在: | Infect Drug Resist |
|---|---|
| Main Authors: | , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6613616/ https://ncbi.nlm.nih.gov/pubmed/31308715 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IDR.S178381 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|